Insiders · AYTU

Gary Cantrell

Director at Aytu Biopharma, Inc (AYTU)

Gary Cantrell has filed 2 insider reports with the SEC since April 2021, as director at Aytu Biopharma, Inc (AYTU). The latest filing, on December 23, 2022, reports sale back to the company at Aytu Biopharma, Inc (AYTU).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where Gary Cantrell is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Aytu Biopharma, Inc logo
AYTU
Aytu Biopharma, Inc
Director164,089$2.66Dec 23, 2022

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Gary Cantrell with

Other insiders at the same companies

Questions about Gary Cantrell

What is Gary Cantrell's role at Aytu Biopharma, Inc?
Gary Cantrell reports to the SEC as director at Aytu Biopharma, Inc (AYTU), according to the latest filing on December 23, 2022.
How many shares does Gary Cantrell own?
After the latest filing that states it, Gary Cantrell directly owned 164,089 shares of Aytu Biopharma, Inc (AYTU). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Gary Cantrell bought or sold stock recently?
No open-market purchases or sales by Gary Cantrell are on file. The filings report sale back to the company and grant or award.
How do I get alerts when Gary Cantrell files?
Follow Gary Cantrell on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Gary Cantrell (SEC CIK 0001679246). Totals count each trade once, skipping amendments whose original is on file, from Apr 16, 2021 on. View on SEC EDGAR · Get this as JSON